483 related articles for article (PubMed ID: 30843268)
1. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
[TBL] [Abstract][Full Text] [Related]
2. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
Coward S; Leggett L; Kaplan GG; Clement F
BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
[TBL] [Abstract][Full Text] [Related]
5. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review.
John-Baptiste A; Yeung MW; Leung V; van der Velde G; Krahn M
Pharmacoeconomics; 2012 Nov; 30(11):1015-34. PubMed ID: 23050771
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
Eckman MH; Ward JW; Sherman KE
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
11. Who to screen for hepatitis C? A cost-effectiveness study in Belgium of comprehensive hepatitis C screening in four target groups.
Opstaele L; Bielen R; Bourgeois S; Moreno C; Nevens F; Robaeys G; Robaeys G; Van Vlierberghe H
Acta Gastroenterol Belg; 2019; 82(3):379-387. PubMed ID: 31566325
[TBL] [Abstract][Full Text] [Related]
12. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
16. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
[TBL] [Abstract][Full Text] [Related]
18. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
Manca F; Robinson E; Dillon JF; Boyd KA
Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of hepatitis C direct acting agents.
Shetty A; Lee M; Valenzuela J; Saab S
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):589-597. PubMed ID: 38665122
[TBL] [Abstract][Full Text] [Related]
20. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
